Costco egg recall for salmonella receives FDA's most severe designation

Title: Costco egg recall for salmonella receives FDA's most severe designation

Article Snip: "...The FDA says that people who bought 24-count packages of organic pasture-raised eggs with UPC 9661910680 under the Kirkland Signature brand — and also bearing the Julian code 327 and a use-by date of Jan 5, 2025 — should bring the products back to Costco or discard them. ..."

Reference: www.npr.org
Costco,Egg Recall, Salmonella, Kirkland Signature Brand, organic pasture-raised eggs,

---

---

Health | Risks and Complications of Breast Implants

Title: Risks and Complications of Breast Implants

Article Snip: "...The FDA has updated the Risks and Complications of Breast Implants, clarifying information about Implant Removal and adding ultrasound as an acceptable alternative imaging for screening for rupture for asymptomatic patients to Silicone Gel-Filled Implant Rupture. The FDA also added a new subsection entitled, Reports of Squamous Cell Carcinoma (SCC), Various Lymphomas other than BIA-ALCL, and Mesenchymal Tumors, including Sarcoma. ..."

Reference:www.fda.gov
Food and Drug Administration (FDA),Breast Implants (Risks and Complications),

---

---

FDA fully approves 'novel' Alzheimer’s disease drug Leqembi, will be covered by Medicare

Title: FDA fully approves 'novel' Alzheimer’s disease drug Leqembi, will be covered by Medicare

Article Snip: "Leqembi has shown clinical benefit in fighting Alzheimer's disease. ...The Food and Drug Administration (FDA) has fully approved a "novel" drug used to treat adult patients with Alzheimer’s, the agency announced. Leqembi, which is produced by Japanese drugmaker Eisai and American-based drugmaker Biogen..."

Reference: www.foxnews.com
Leqembi,Medicare,Alzheimer's, Health,Alzheimer’s Drugs,Food and Drug Administration (FDA),amyloid beta-directed antibody, Biogen, Eisai, Lecanemab,

---

---

Medicare will continue to restrict coverage of a new class of Alzheimer’s drugs, even when fully approved by the Food and Drug Administration (FDA)

Title: Medicare won’t change coverage policy for pricey Alzheimer’s drugs

Article Snip: "Currently, Medicare coverage is even stricter, as the agency will only pay for the drugs if a patient receives them through a clinical trial. The treatments in question are monoclonal antibody infusions that target brain plaque known as amyloid that’s a signature characteristic of Alzheimer’s disease. The drugs are intended for early stage Alzheimer’s patients and are meant to slow the progression of memory loss, but are not a cure. They are costly, and there are only two: Eisai’s Leqembi and Biogen’s Aduhelm. Both were granted accelerated approval by FDA..."

Reference: www.yahoo.com
Centers for Medicare and Medicaid Services (CMS)

---

---